Hyperprolactinemia-Related Adverse Events Associated with Antipsychotic Treatment in Children and Adolescents

Journal of Adolescent Health

Volumn 45, Issue 1, 2009, Pages 70-76

  Jerrell, Jeanette M ^a   Bacon, Janice ^a   Burgis, Judith T ^a   Menon, Seema ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescents; Anticonvulsants; Antidepressants; Antipsychotics; Sexual side effects

Indexed keywords

ARIPIPRAZOLE; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VALPROATE SEMISODIUM; VALPROIC ACID DERIVATIVE; ZIPRASIDONE;

AMENORRHEA; ARTICLE; CHILD; COMORBIDITY; CONTROLLED STUDY; ENDOCRINE DISEASE; ERECTILE DYSFUNCTION; FEMALE; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS DISEASE; IMPOTENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OBESITY; OLIGOMENORRHEA; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; COHORT STUDIES; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; PROPORTIONAL HAZARDS MODELS; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SOUTH CAROLINA;

EID: 67349119838     PISSN: 1054139X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jadohealth.2008.11.010     Document Type: Article

References (30)

1. Mancini T., Casaneuva F.F., and Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin N Am 37 (2008) 67-99
2. Haddad P.M., and Wieck A. Antipsychotic-induced hyperprolactinemia: mechanisms, clinical features, and management. Drugs 64 20 (2004) 2291-2314
3. Molitch M.E. Disorders of PRL secretion. Endocrinol Metab Clin N Am 30 3 (2001) 585-610
4. Molitch M.E. Medication-induced hyperprolactinemia. Mayo Clinic Proc 80 8 (2005) 1050-1057
5. Romeo J.H., Dombrowski R., Kwak Y.S., et al. Hyperprolactinemia and verapamil: prevalence and potential association with hypogonadism in men. Clin Endocrinol (Oxf) 45 5 (1996) 571-575
6. Byerly M., Suppes T., Tran Q.V., and Baker R.A. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders. J Clin Psychopharmacol 27 6 (2007) 639-661
7. McIntyre R.S., Soczynska J.K., Konarski J.Z., and Kennedy S.H. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 5 1 (2006) 157-168
8. Baker S., Barlow S., Cochran W., et al. Overweight children and adolescents: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 40 (2005) 533-543
9. Findling R.L., Steiner H., and Weller E.B. Use of antipsychotics in children and adolescents. J Clin Psychiatry 66 Suppl 7 (2005) 29-40
10. Patel N.C., Crismon M.L., Hoagwood K., et al. Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents. J Child Adolesc Psychopharm 15 (2005) 270-284
11. Zito J.M., Safer D.J., dosReis S., et al. Psychotropic practice patterns for youth: A 10-year perspective. Arch Pediatr Adolesc Med 157 (2003) 17-25
12. Toren P., Ratner S., Laor N., et al. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Safety 27 14 (2004) 1135-1156
13. Goodnick P.J., Rodriguez L., and Santana O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother 3 10 (2002) 1381-1391
14. Kim K.S., Pae C.U., Chae J.H., et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatr 63 5 (2002) 408-413
15. Tohen M., Kryzhanovskaya L., Carlson G., et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 164 10 (2007) 1547-1556
16. Kelly D.L., Love R.C., Mackowick M., et al. Atypical antipsychotic use in a state hospital inpatient adolescent population. J Child Adolesc Psychopharmacol 14 (2004) 75-85
17. Cheng-Shannon J., McGough J.J., Pataki C., et al. Second generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 14 (2004) 372-394
18. Correll C.U., Penzner J.B., Parikh U.H., et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatric Clin N Am 15 (2006) 177-206
19. McIntyre R.S., and Konarski J.Z. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 66 Suppl 3 (2005) 28-36
20. Correll C.U., and Carlson H.E. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 45 (2006) 771-791
21. Hu X.H., Bull S.A., Hunkeler E.M., et al. Incidence and duration of side effects and those rated as bothersome with SSRI treatment for depression: patient report versus physician estimate. J Clin Psychiatry 65 (2004) 959-965
22. Burke M.J., and Lincoln J. Mood disorders. In: Bakel R.E., and Bope E.T. (Eds). Conn's Current Therapy 2006 (2006), WB Saunders Co., Philadelphia, PA 1361-1370
23. Damsa C., Bumb A., Bianchi-Demicheli F., et al. Dopamine dependent" side effects of SSRIs: a clinical review. J Clin Psychiatry 65 (2004) 1064-1068
24. Ellsworth A.J., Witt D.M., Dugdale D.C., et al. Mosby's Medical Drug Reference (2006), Mosby, St. Louis, MO
25. Patterson W.M. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 54 (1993) 71
26. Gold Standard, Inc. Citalopram, Escitalopram, Fluoxetine, Fluoxetine+Olanzapine, Fluvoxamine, Paroxetine, and Sertraline: Adverse Reactions. MD Consult [database] 2008. Columbia, SC: University of South Carolina School of Medicine Library. Accessed January 30, 2008.
27. Hirschfeld R.M.A. The role of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 66 Suppl 3 (2005) 3-4
28. Masand P.S., and Gupta S. Long-term side effects of newer-generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry 14 3 (2002) 175-182
29. Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry 66 6 (2005) 761-767
30. Isojarvi J.I.T., Laatikainen T.J., Pakarinen A.J., et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 329 (1993) 1383-1388